Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report) saw a significant growth in short interest in June. As of June 30th, there was short interest totaling 8,252 shares, a growth of 77.0% from the June 15th total of 4,661 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. Currently, 0.0% of the company’s stock are sold short.
Innate Pharma Price Performance
Shares of IPHYF stock opened at $1.65 on Friday. The business’s fifty day moving average is $1.75 and its 200 day moving average is $1.85. Innate Pharma has a twelve month low of $1.37 and a twelve month high of $2.25.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
Recommended Stories
- Five stocks we like better than Innate Pharma
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
